vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
31.20
+0.18 (0.58%)
Jul 28, 2026, 3:21 PM EDT - Market open
vTv Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 1.02 | - | 2.02 | 4.01 | |
Revenue Growth | - | - | - | - | -49.61% | -37.56% |
Gross Profit | - | - | 1.02 | - | 2.02 | 4.01 |
Selling, General & Admin | 15.87 | 14.95 | 13.65 | 11.91 | 12.2 | 12.34 |
Research & Development | 24.01 | 17.86 | 11.55 | 13.6 | 12.36 | 13.32 |
Total Operating Expenses | 39.88 | 32.81 | 25.2 | 25.5 | 24.56 | 25.67 |
Operating Income | -3.04 | -32.81 | -24.18 | -25.5 | -22.54 | -21.66 |
Interest Income | 2.38 | 1.87 | 1.57 | 0.47 | 0.35 | 0 |
Interest Expense | - | -0.01 | - | -0.01 | -0.02 | -0.01 |
Other Non-Operating Income (Expense) | 0.03 | -0.14 | 0.01 | -0.92 | -2.67 | 4.06 |
Total Non-Operating Income (Expense) | 2.4 | 1.73 | 1.58 | -0.46 | -2.33 | 4.05 |
Pretax Income | -0.73 | -31.08 | -22.61 | -25.97 | -24.87 | -17.62 |
Provision for Income Taxes | - | - | 0.1 | - | 0.2 | 0.12 |
Net Income | -0.73 | -31.08 | -22.71 | -25.97 | -25.07 | -17.73 |
Minority Interest in Earnings | -2.98 | -4.11 | -4.24 | -5.72 | -5.91 | -4.74 |
Net Income to Common | 2.25 | -26.97 | -18.46 | -20.25 | -19.16 | -12.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 10 | 8 | 6 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 10 | 8 | 6 | 2 | 2 | 2 |
Shares Change | 66.57% | 45.96% | 176.79% | 8.60% | 22.58% | 32.90% |
EPS (Basic) | -0.64 | -3.20 | -3.20 | -9.71 | -9.98 | -8.29 |
EPS (Diluted) | -0.93 | -3.20 | -3.20 | -9.71 | -9.98 | -8.29 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -10.41 | -25.26 | -25.31 | -19.08 | -16.04 | -19.31 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.00 | -3.00 | -4.39 | -9.15 | -8.36 | -12.33 |
Gross Margin | - | - | 100.00% | - | 100.00% | 100.00% |
Operating Margin | - | - | -2377.58% | - | -1116.95% | -540.87% |
Profit Margin | - | - | -2232.55% | - | -1242.47% | -442.72% |
FCF Margin | - | - | -2488.40% | - | -795.00% | -482.10% |
EBITDA | -3.03 | -32.79 | -24.09 | -25.41 | -22.45 | -21.57 |
EBITDA Margin | - | - | -2368.83% | - | -1112.39% | -538.65% |
EBIT | -3.04 | -32.81 | -24.18 | -25.5 | -22.54 | -21.66 |
EBIT Margin | - | - | -2377.58% | - | -1116.95% | -540.87% |
Effective Tax Rate | - | 0.00% | -0.44% | 0.00% | -0.80% | -0.65% |